Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?
Identifieur interne : 000B38 ( Main/Merge ); précédent : 000B37; suivant : 000B39Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?
Auteurs : Jobert Richie N. Nansseu [Cameroun] ; Jean Joel R. Bigna [Cameroun]Source :
- Infectious diseases of poverty [ 2049-9957 ] ; 2017.
Descripteurs français
- KwdFr :
- Afrique subsaharienne (épidémiologie), Agents antiVIH (effets indésirables), Agents antiVIH (usage thérapeutique), Humains, Infections à VIH (diagnostic), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Infections à VIH (épidémiologie), Organisation mondiale de la santé, Pauvreté, Politique de santé, Prévalence, Syndrome d'immunodéficience acquise (traitement médicamenteux), Syndrome d'immunodéficience acquise (virologie), Thérapie antirétrovirale hautement active (effets indésirables).
- MESH :
- diagnostic : Infections à VIH.
- effets indésirables : Agents antiVIH, Thérapie antirétrovirale hautement active.
- traitement médicamenteux : Infections à VIH, Syndrome d'immunodéficience acquise.
- usage thérapeutique : Agents antiVIH.
- virologie : Infections à VIH, Syndrome d'immunodéficience acquise.
- épidémiologie : Afrique subsaharienne, Infections à VIH.
- Humains, Organisation mondiale de la santé, Pauvreté, Politique de santé, Prévalence.
English descriptors
- KwdEn :
- Acquired Immunodeficiency Syndrome (drug therapy), Acquired Immunodeficiency Syndrome (virology), Africa South of the Sahara (epidemiology), Anti-HIV Agents (adverse effects), Anti-HIV Agents (therapeutic use), Antiretroviral Therapy, Highly Active (adverse effects), HIV Infections (diagnosis), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV Infections (virology), Health Policy, Humans, Poverty, Prevalence, World Health Organization.
- MESH :
- chemical , adverse effects : Anti-HIV Agents.
- adverse effects : Antiretroviral Therapy, Highly Active.
- diagnosis : HIV Infections.
- drug therapy : Acquired Immunodeficiency Syndrome, HIV Infections.
- epidemiology : Africa South of the Sahara, HIV Infections.
- chemical , therapeutic use : Anti-HIV Agents.
- virology : Acquired Immunodeficiency Syndrome, HIV Infections.
- Health Policy, Humans, Poverty, Prevalence, World Health Organization.
Abstract
Recent studies have shown that early antiretroviral therapy (ART) initiation results in significant HIV transmission reduction. This is the rationale behind the "test and treat" policy of the World Health Organization (WHO). Implementation of this policy will lead to an increased incidence of ART-related adverse effects, especially in sub-Saharan Africa (SSA). Is the region yet ready to cope with such a challenging issue?
DOI: 10.1186/s40249-017-0240-3
PubMed: 28196511
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000617
- to stream PubMed, to step Curation: 000617
- to stream PubMed, to step Checkpoint: 000617
- to stream Ncbi, to step Merge: 003E11
- to stream Ncbi, to step Curation: 003E11
- to stream Ncbi, to step Checkpoint: 003E11
Links to Exploration step
pubmed:28196511Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?</title><author><name sortKey="Nansseu, Jobert Richie N" sort="Nansseu, Jobert Richie N" uniqKey="Nansseu J" first="Jobert Richie N" last="Nansseu">Jobert Richie N. Nansseu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Faculty of Medicine and Biomedical Sciences of the University of Yaoundé I, PO Box 1364, Yaoundé, Cameroon. jobertrichie_nansseu@yahoo.fr.</nlm:affiliation><country xml:lang="fr">Cameroun</country><wicri:regionArea>Department of Public Health, Faculty of Medicine and Biomedical Sciences of the University of Yaoundé I, PO Box 1364, Yaoundé</wicri:regionArea><wicri:noRegion>Yaoundé</wicri:noRegion></affiliation></author><author><name sortKey="Bigna, Jean Joel R" sort="Bigna, Jean Joel R" uniqKey="Bigna J" first="Jean Joel R" last="Bigna">Jean Joel R. Bigna</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé, Cameroon.</nlm:affiliation><country xml:lang="fr">Cameroun</country><wicri:regionArea>Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé</wicri:regionArea><wicri:noRegion>Yaoundé</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28196511</idno><idno type="pmid">28196511</idno><idno type="doi">10.1186/s40249-017-0240-3</idno><idno type="wicri:Area/PubMed/Corpus">000617</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000617</idno><idno type="wicri:Area/PubMed/Curation">000617</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000617</idno><idno type="wicri:Area/PubMed/Checkpoint">000617</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000617</idno><idno type="wicri:Area/Ncbi/Merge">003E11</idno><idno type="wicri:Area/Ncbi/Curation">003E11</idno><idno type="wicri:Area/Ncbi/Checkpoint">003E11</idno><idno type="wicri:Area/Main/Merge">000B38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?</title><author><name sortKey="Nansseu, Jobert Richie N" sort="Nansseu, Jobert Richie N" uniqKey="Nansseu J" first="Jobert Richie N" last="Nansseu">Jobert Richie N. Nansseu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Public Health, Faculty of Medicine and Biomedical Sciences of the University of Yaoundé I, PO Box 1364, Yaoundé, Cameroon. jobertrichie_nansseu@yahoo.fr.</nlm:affiliation><country xml:lang="fr">Cameroun</country><wicri:regionArea>Department of Public Health, Faculty of Medicine and Biomedical Sciences of the University of Yaoundé I, PO Box 1364, Yaoundé</wicri:regionArea><wicri:noRegion>Yaoundé</wicri:noRegion></affiliation></author><author><name sortKey="Bigna, Jean Joel R" sort="Bigna, Jean Joel R" uniqKey="Bigna J" first="Jean Joel R" last="Bigna">Jean Joel R. Bigna</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé, Cameroon.</nlm:affiliation><country xml:lang="fr">Cameroun</country><wicri:regionArea>Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé</wicri:regionArea><wicri:noRegion>Yaoundé</wicri:noRegion></affiliation></author></analytic><series><title level="j">Infectious diseases of poverty</title><idno type="eISSN">2049-9957</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acquired Immunodeficiency Syndrome (drug therapy)</term><term>Acquired Immunodeficiency Syndrome (virology)</term><term>Africa South of the Sahara (epidemiology)</term><term>Anti-HIV Agents (adverse effects)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Antiretroviral Therapy, Highly Active (adverse effects)</term><term>HIV Infections (diagnosis)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (virology)</term><term>Health Policy</term><term>Humans</term><term>Poverty</term><term>Prevalence</term><term>World Health Organization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique subsaharienne (épidémiologie)</term><term>Agents antiVIH (effets indésirables)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Humains</term><term>Infections à VIH (diagnostic)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Infections à VIH (épidémiologie)</term><term>Organisation mondiale de la santé</term><term>Pauvreté</term><term>Politique de santé</term><term>Prévalence</term><term>Syndrome d'immunodéficience acquise (traitement médicamenteux)</term><term>Syndrome d'immunodéficience acquise (virologie)</term><term>Thérapie antirétrovirale hautement active (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Acquired Immunodeficiency Syndrome</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term><term>Thérapie antirétrovirale hautement active</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Africa South of the Sahara</term><term>HIV Infections</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term><term>Syndrome d'immunodéficience acquise</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term><term>Syndrome d'immunodéficience acquise</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Acquired Immunodeficiency Syndrome</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Afrique subsaharienne</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Health Policy</term><term>Humans</term><term>Poverty</term><term>Prevalence</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Organisation mondiale de la santé</term><term>Pauvreté</term><term>Politique de santé</term><term>Prévalence</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent studies have shown that early antiretroviral therapy (ART) initiation results in significant HIV transmission reduction. This is the rationale behind the "test and treat" policy of the World Health Organization (WHO). Implementation of this policy will lead to an increased incidence of ART-related adverse effects, especially in sub-Saharan Africa (SSA). Is the region yet ready to cope with such a challenging issue?</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000B38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:28196511
|texte= Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:28196511" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |